DYRK1A and breast carcinoma: While DYRK1A has a low mutational count in breast cancer (only 2.5% amplification mutations), these patients (altered group) mostly exhibit aggressive tumors (histological grade 2 and 3) with ER-/PR- status and are more likely categorized as patients who received chemotherapy (Fig. 1c–g).